Note 9. Share-based Compensation:

During the nine months ended March 31, 2026 and 2025, the Company granted 1.0 million and 0.8 million stock options at weighted average grant prices of $53.98 and $74.63 and weighted average fair values of $19.15 and $25.44, respectively. During the nine months ended March 31, 2026 and 2025, the Company granted 0.6 million and 0.5 million restricted stock units at a weighted average fair value of $53.70 and $74.95, respectively. During the nine months ended March 31, 2026 and 2025, the Company granted 13,120 and 12,736 shares of restricted common stock shares at a weighted average fair value of $60.96 and $68.67, respectively.

Stock options for 2.1 million and 1.1 million shares of common stock with total intrinsic values of $32.8 million and $35.7 million were exercised during the nine months ended March 31, 2026 and 2025, respectively.

Stock-based compensation expense, inclusive of payroll taxes, of $10.4 million and $11.2 million was included in Selling, general and administrative expenses for the quarter ended March 31, 2026 and 2025, respectively. Stock-based compensation expenses, inclusive of payroll taxes, of $35.4 million and $36.0 million was included in Selling, general, and administrative expenses for the nine months ended March 31, 2026 and 2025, respectively. Additionally, the Company recognized $0.4 million and $0.4 million of stock-based compensation costs, inclusive of payroll taxes, in Cost of goods sold for the quarter ended March 31, 2026 and 2025, respectively. Stock-based compensation expense, inclusive of payroll taxes, of $1.3 million and $1.0 million was included in Cost of goods sold for the nine months ended March 31, 2026 and 2025. As of March 31, 2026, there was $40.8 million of unrecognized compensation cost related to non-vested stock options, non-vested restricted stock units and non-vested restricted stock. The weighted average period over which the compensation cost is expected to be recognized is 2.0 years.